Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
4.740
-0.190 (-3.85%)
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Coya Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Analyst Expectations for Coya Therapeutics's Future
↗
July 17, 2023
Via
Benzinga
Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation
↗
July 17, 2023
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients
Via
Benzinga
Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease
July 17, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth
↗
July 12, 2023
Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this...
Via
Benzinga
The Latest Analyst Ratings for Coya Therapeutics
↗
June 08, 2023
Via
Benzinga
Coya Therapeutics: Another Sucess
↗
May 16, 2023
The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company.
Via
Talk Markets
Why Coya Therapeutics Shares Are Shooting Higher Today
↗
May 16, 2023
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in
Via
Benzinga
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
July 05, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC)
June 28, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)
June 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs
June 14, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
June 12, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease
June 08, 2023
Via
Get News
Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
↗
June 08, 2023
Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close...
Via
Benzinga
Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation
↗
June 07, 2023
Coya Therapeutics Inc (NASDAQ: COYA) reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
June 07, 2023
Via
Benzinga
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)
June 07, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
↗
June 06, 2023
Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
June 06, 2023
It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning!
Via
InvestorPlace
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD)
June 05, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
June 01, 2023
Via
Benzinga
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
May 22, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
↗
May 18, 2023
Via
Benzinga
Tesla, Manchester United, Ohmyhome, Target, Coya: Why These 5 Stocks Are Drawing Investor Attention Today
↗
May 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 16, 2023
Via
Benzinga
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
May 16, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
May 10, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET
May 09, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Positive Financials Along With Promising Clinical Results – Coya Therapeutics
↗
May 08, 2023
Howard Berman, Ph.D., CEO & Chairman of the Board of Coya Therapeutics, Inc. (NASDAQ: COYA), was recently a guest on Benzinga’s All Access.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
↗
May 03, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
